Uterine Sarcomas: 10 Years of Experience at a Single Institution

Abstract

INTRODUCTION[|]The present study aims to evaluate the sociodemographic characteristics and clinical management of patients with uterine sarcoma.[¤]METHODS[|]Retrospective analysis of 55 patients, who were diagnosed with uterine sarcomas between January 1, 2004–January 1, 2014, was performed. Sociodemographic characteristics, methods used in diagnosis and treatment processes were investigated by accessing the medical files of the patients. All patients were contacted by telephone to obtain information about disease progression and recurrence. Patients' death reports were obtained from the national database of the Ministry of Health and the findings were analyzed statistically. [¤]RESULTS[|]In this study, 55 cases of uterine sarcoma, of whom 31 carcinosarcomas (56.4%), 15 leiomyosarcomas (27.3%), six endometrial stromal sarcomas (10.9%) and three adenosarcomas (5.5%) were analyzed. The median age was 60.75+-12.74 (min-max: 33–86). Forty-three (78.2%) patients were in postmenopausal period. Twenty-seven (47.3%) of these patients were diagnosed by endometrial sampling, 17 (30.9%) patients were diagnosed by frozen section, 11 (20%) patients were diagnosed by hysterectomy and one (1.81%) patient was diagnosed by myomectomy. Three patients had distant metastases at the time of diagnosis. According to FIGO (International Federation of Gynecology and Obstetrics) 2009, 65.5% of the patients were diagnosed at stage 1. 58.5% of the patients who underwent surgery were operated by gynecologist-oncologist. Total abdominal hysterectomy with bilateral salping-oopherectomy was performed in 52 patients (94.5%). Pelvic lymph node dissection was performed in 28 patients (51%). The mean survival time was 47 months in carcinosarcoma, 49.6 months in leiomyosarcoma, 84.8 months in endometrial stromal sarcoma and 68.7 months in adenosarcoma. Until the last date of collecting data, January 2019, 37 patients (67.3%) died. [¤]DISCUSSION AND CONCLUSION[|]Uterine sarcomas are rare tumors with poor prognosis even in the early stages. Each histological type should be evaluated separately. Surgery is the main treatment method in uterine sarcoma. The role of adjuvant therapy is controversial.[¤]

Keywords

• adenosarcoma
• carcinosarcoma; endometrial stromal sarcoma; leiomyosarcoma; uterine sarcoma.